Health Outcomes Research in Medicine
Volume 1, Issue 2 , Pages e93-e102 , December 2010

Incidence of Exacerbations and Hospitalizations Is Reduced and Time to Exacerbations Is Prolonged with Mometasone Furoate Dry Powder Inhaler Versus Beclomethasone Dipropionate Hydrofluoroalkane Aerosol in Patients with Mild Asthma

  • Prakash Navaratnam, RPh, MPH, PhD

      Affiliations

    • Eympres Research, LLC, Hilliard, Ohio
    • Corresponding Author InformationCorresponding Author: Prakash Navaratnam, RPh, MPH, PhD, Eympres Research, LLC, 4660 Stonehill St., Hilliard, OH 43026.
    • ,
  • Eduardo Urdaneta, MD

      Affiliations

    • Schering-Plough Corporation, Kenilworth, New Jersey
    • ,
  • John McLaughlin, MSPH

      Affiliations

    • Informagenics, LLC, Worthington, Ohio
    • ,
  • Howard S. Friedman, PhD, MMS

      Affiliations

    • Analytic Solutions, LLC, New York, New York

References 

  1. National Asthma Education and Prevention Program . Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report; 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/index.htmAccessed January 19, 2010
  2. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99
  3. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007;30:452–456
  4. Emerman CL, Woodruff PG, Cydulka RK, Gibbs MA, Pollack CV, Camargo CA. Prospective multicenter study of relapse following treatment for acute asthma among adults presenting to the emergency department. MARC investigators. Multicenter Asthma Research Collaboration. Chest. 1999;115:919–927
  5. Alvarez GG, Schulzer M, Jung D, Fitzgerald JM. A systematic review of risk factors associated with near-fatal and fatal asthma. Can Respir J. 2005;12:265–270
  6. Sin DD, Man J, Sharpe H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA. 2004;292:367–376
  7. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest. 2004;125:1081–1102
  8. Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B, Silverman S. Risk factors and costs associated with an asthma attack. Thorax. 2000;55:19–24
  9. Teva Specialty Pharmaceuticals. Qvar (beclomethasone dipropionate) package insert. Horsham, PA: Teva Specialty Pharmaceuticals; 2008;
  10. Merck & Co. Asmanex Twisthaler® (mometasone furoate) package insert. Whitehouse Station, NJ: Merck & Co.; 2008;
  11. Kemp L, Price D, Sims E, Dorinsky P, von Ziegenweidt J. ‘Real-life’ effectiveness of Qvar, beclomethasone and fluticasone. J Allergy Clin Immunol. 2009;123:729;[Abstract]
  12. Friedman HS, Urdaneta E, McLaughlin JM, Navaratnam P. Mometasone furoate versus beclomethasone dipropionate: effectiveness in patients with mild asthma. Am J Manag Care. 2010;16:e151–e156
  13. National Center for Health Statistics, Centers for Disease Control and Prevention. International Classification of Diseases. Hyattsville, MD: National Center for Health Statistics; 2008;9th Revision, Clinical Modification
  14. Friedman HS, Yawn BP. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids. Curr Med Res Opin. 2007;23:427–434
  15. Allen-Ramey FC, Bukstein D, Luskin A, Sajjan SG, Markson LE. Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. J Manag Care Pharm. 2006;12:310–321
  16. Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S. Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med. 2006;48:794–802
  17. Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24
  18. Paparrigopoulos T, Melissaki A, Efthymiou A, et al. Short-term psychological impact on family members of intensive care unit patients. J Psychosom Res. 2006;61:719–722
  19. Suesada MM, Martins MA, Carvalho CR. Effect of short-term hospitalization on functional capacity in patients not restricted to bed. Am J Phys Med Rehabil. 2007;86:455–462
  20. Dusser D, Montani D, Chanez P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62:591–604
  21. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med. 2005;352:1519–1528
  22. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1392–1397
  23. Krishnan JA, Riekert KA, McCoy JV, et al. Corticosteroid use after hospital discharge among high-risk adults with asthma. Am J Respir Crit Care Med. 2004;170:1281–1285
  24. Molimard M, Le Gros V. Impact of patient-related factors on asthma control. J Asthma. 2008;45:109–113
  25. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004;114:1288–1293
  26. Stern L, Berman J, Lumry W, et al. Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data. Ann Allergy Asthma Immunol. 2006;97:402–408
  27. Nathan RA, Nayak AS, Graft DF, et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol. 2001;86:203–210
  28. Noonan M, Leflein J, Corren J, Staudinger H. Long-term safety of mometasone furoate administered via a dry powder inhaler in children: results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma. BMC Pediatr. 2009;9:43
  29. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469–478

 This work was supported by Merck & Co., Kenilworth, New Jersey.

 Prakash Navaratnam is a paid consultant for Merck & Co.; Eduardo Urdaneta was an employee of Merck & Co. (then Schering-Plough Corporation) when this study was conducted; John McLaughlin is a paid consultant for Merck & Co and is employed as a research scientist at Informagenics, LLC; Howard S. Friedman is the owner of Analytic Consulting, LLC, which performs consulting work in the pharmaceutical industry, including Merck & Co.

PII: S1877-1319(10)00011-X

doi: 10.1016/j.ehrm.2010.08.001

Health Outcomes Research in Medicine
Volume 1, Issue 2 , Pages e93-e102 , December 2010

Article Tools

* Image Usage & Resolution